BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 28
• 29
• 30
• 31

• Drug Development

  Dr. Janet Hoogstraate New Board Member of AlzeCure Pharma

  AlzeCure Pharma AB announced that Janet Hoogstraate is newly elected to AlzeCure’s board.

  May 19, 2023

   · 

  2 min read
• Alvotech Reports Financial Results for First three Months of 2023 and Provides Business Update

  Alvotech, a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, reported unaudited financial results for the first three months of 2023 and provided a summary of recent corporate highlights.

  May 19, 2023

   · 

  18 min read
• Drug Development

  Epic Bio Presents Preclinical Data on EPI-321 for Facioscapulohumeral Muscular Dystrophy at ASGCT 26th Annual Meeting

  Epic Bio, a biotechnology company developing therapies to modulate gene expression using compact, non-cutting dCas proteins, presented promising preclinical data supporting development of EPI-321 for the treatment of facioscapulohumeral muscular dystrophy.

  May 19, 2023

   · 

  2 min read
• Biotech Bay

  Metagenomi Presents New Data on Novel Gene Editing Systems at the 26th American Society of Gene + Cell Therapy (ASGCT) Annual Meeting

  Metagenomi, a genetic medicines company with a versatile portfolio of wholly owned, next-generation gene editing systems, presented new data for its gene editing programs during the 26th American Society of Gene + Cell Therapy Annual Meeting.

  May 19, 2023

   · 

  6 min read
• Biotech Bay

  Reviva Pharmaceuticals Joins Webull Corporate Communications Service Platform

  Reviva Pharmaceuticals Holdings, Inc. announced the Company has joined Webull’s Corporate Communications Service Platform.

  May 19, 2023

   · 

  5 min read
• Drug Development

  Kymera Therapeutics Doses First Patient in Phase 1 Oncology Trial of MDM2 Degrader KT-253

  Kymera Therapeutics, Inc. has recently dosed the first patient in the Phase 1 multicenter, open-label, dose-escalation clinical trial evaluating its investigational MDM2 degrader KT-253.

  May 19, 2023

   · 

  6 min read
• Business

  Catalent to Hold Business Update Call Related to Delay of Third Quarter 2023 Results and Receives NYSE Notice Regarding Late Form 10-Q Filing

  Catalent to Hold Business Update Call Related to Delay of Third Quarter 2023 Results and Receives NYSE Notice Regarding Late Form 10-Q Filing.

  May 19, 2023

   · 

  5 min read
• Lone Star Bio

  Taysha Gene Therapies Presents Preclinical Data on TSHA-102 for Rett Syndrome Demonstrating Cellular Regulation of MeCP2 Expression in Key Mouse Models at the American Society of Gene and Cell Therapy 26th Annual Meeting

  Taysha Gene Therapies today presents preclinical data from neonatal mouse models on TSHA-102 for Rett syndrome, including new data in wild-type mice, at the American Society of Gene and Cell Therapy (ASGCT) 26th Annual Meeting.

  May 19, 2023

   · 

  7 min read
• Business

  AMYRIS COMPLETES LICENSE FOR SUPPLY OF SUSTAINABLE SQUALENE

  Amyris, Inc. today announced that it has signed an exclusive license agreement with British specialty chemicals company Croda International Plc, or the supply of sustainable squalene.

  May 19, 2023

   · 

  5 min read
• SAB Biotherapeutics Presents Virtual 2023 R&D Day Portfolio Update: Breakthrough Immunotherapy Innovations

  SAB Biotherapeutics (NASDAQ: SABS) announced today that it will be hosting its Virtual 2023 Annual R&D Day on Wednesday, June 14, 2023, at 1:30 P.M. CT.

  May 19, 2023

   · 

  4 min read